Recent News

• 09.29.2025 - BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
• 09.29.2025 - BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
• 08.14.2025 - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
• 08.14.2025 - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
• 08.14.2025 - BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.14.2025 - BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.07.2025 - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
• 08.07.2025 - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
• 06.29.2025 - 2025 Annual Meeting of Shareholders
• 06.29.2025 - 2025 Annual Meeting of Shareholders

Recent Filings

• 09.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]